Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Matthew Snape is a guest on Sierra Leone's radio programme Pikin to Pikin Tok.

Matthew discusses the work of the Department's vaccine group on Ebola vaccines on 'Pikin to Pikin Tok' (which means child to child talk in the local language Krio), a radio series launched during the Ebola crisis. You can listen to the programme here.

The UK child rights agency 'Child to Child' and their partner in Sierra Leone, 'the Pikin to Pikin movement' were running a project in the east of Sierra Leone (in the impoverished Kailahun region where the first case of Ebola was reported) since 2011. This project aimed to enhance children's social, literacy, numeracy and life skills, but the Ebola crisis meant that the NGO's work, which required children to come together in groups, had to stop due to the health risk such gatherings would create.

'Child to Child' decided to turn to radio and commissioned radio producer Penny Boreham, who also works for BBC World Service, to produce the programmes about staying healthy during the crisis and its aftermath.

The radio project, which broadcasts Storytime programmes, music programmes and special programmes like this one on the new Ebola vaccines, is funded by Comic Relief and presented by Sierra Leonean storyteller, Usifu Jalloh.

Similar stories

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

COVID-19 Research Vaccinology

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

Oxford vaccine effective against major B.1.1.7 ‘Kent’ coronavirus strain circulating in the UK

COVID-19 Research Vaccinology

A preprint of ongoing work to assess effectiveness of Oxford’s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 ‘Kent’ coronavirus strain currently circulating in the UK to previously circulating variants.

Oxford leads first trial investigating dosing with alternating vaccines

COVID-19 Clinical Trials Vaccinology

The University of Oxford is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.

Oxford University vaccine developer joins day of vaccinations at the Kassam Stadium

COVID-19 Vaccinology

Today, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.

First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy

COVID-19 Vaccinology

University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.

Oxford University breakthrough on global COVID-19 vaccine

COVID-19 Vaccinology

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.